Evolving Anatomic, Functional, and Molecular Imaging in the Early Detection and Prognosis of Hypertrophic Cardiomyopathy

Fuster, Valentín; Zee, Sarina van der; Miller, Marc A.

doi:10.1007/s12265-009-9133-6

Cited by 4 publications

(2 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LGE was not seen in any of the mutation carriers in this study, including CMR LVH+ subjects and subjects that developed overt HCM during follow-up. Although there have been rare reports of LGE in G+/LVH− adults, 28–31 LGE does not seem to be a characteristic feature of early/emerging disease. Nevertheless, there is evidence of increased collagen synthesis in sarcomere mutation carriers without LVH.…”

Section: Discussionmentioning

confidence: 91%

Comparison of Echocardiographic and Cardiac Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers Without Left Ventricular Hypertrophy

Valente

Lakdawala

Powell

et al. 2013

Circ Cardiovasc Genet

View full text Add to dashboard Cite

Background Left ventricular hypertrophy (LVH) typically manifests during or after adolescence in sarcomere mutation carriers at risk for developing hypertrophic cardiomyopathy. Guidelines recommend serial imaging of mutation carriers without LVH (G+/LVH−) to monitor for phenotypic evolution, but the optimal strategy is undefined. Compared with echocardiography (echo), cardiac MRI (CMR) offers improved endocardial visualization and potential to assess scar. However, the incremental advantage offered by CMR for early diagnosis of hypertrophic cardiomyopathy is unclear. Therefore, we systematically compared echo and CMR in G+/LVH− subjects. Methods and Results A total of 40 sarcomere mutation carriers with normal echo wall thickness (<12 mm or z score <2.5 in children) underwent concurrent CMR. Mean age was 21.7±11.1 years, 55% were female. If left ventricular wall thickness seemed nonuniform, the size and location of relatively thickened segments were noted. Late gadolinium enhancement was assessed with CMR. Diagnostic agreement between echo and CMR was good (90%), although CMR measurements of left ventricular wall thickness were ≈19% lower than echo. Four subjects had mild hypertrophy (12.6–14 mm; ≤2 segments) appreciated by CMR but not echo. No subjects had late gadolinium enhancement. During median 35-month follow-up, 2 subjects developed overt hypertrophic cardiomyopathy, including 1 with mild LVH by CMR at baseline. Conclusions Echo is unlikely to miss substantial LVH; however, CMR identified mild hypertrophy in ≈10% of mutation carriers with normal echo wall thickness. CMR may be a useful adjunct in hypertrophic cardiomyopathy family screening, particularly in higher risk situations, or if echocardiographic images are suboptimal or suggest borderline LVH.

show abstract

Section: Discussionmentioning

confidence: 91%

Comparison of Echocardiographic and Cardiac Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers Without Left Ventricular Hypertrophy

Valente

Lakdawala

Powell

et al. 2013

Circ Cardiovasc Genet

View full text Add to dashboard Cite

show abstract

“…Deformation imaging has already proven its value in, for example, hypertrophic cardiomyopathy (Fuster, Van Der Zee, & Miller, 2009) and valvular heart disease (Casas-Rojo et al, 2016;Gunjan, Kurien, & Tyagi, 2012), in which deterioration of deformation parameters can be observed before LVEF decreases. This apparent superior sensitivity for changes in cardiac function makes deformation imaging of great potential use within cardiac regenerative medicine.…”

Section: Discussionmentioning

confidence: 99%

Deformation imaging to assess global and regional effects of cardiac regenerative therapy in ischaemic heart disease: A systematic review

Klarenbosch

Chamuleau

Teske

2019

J Tissue Eng Regen Med

View full text Add to dashboard Cite

Currently, left ventricular ejection fraction (LVEF) is the most common endpoint in cardiovascular stem cell therapy research. However, this global measure of cardiac function might not be suitable to detect the regional effects sorted by this therapy and is hampered by high operator variability and loading dependency. Deformation imaging might be more accurate in detecting potential regional functional improvements by cardiac regenerative therapy. The aim of this systematic review is to provide a comprehensive overview of current literature on the value of deformation imaging in cardiac regenerative therapy. A systematic review of current literature available on PubMed, Embase, and Cochrane databases was performed regarding both animal and patient studies in which deformation imaging was used to study cardiac cell therapy. After critical appraisal, outcomes regarding study design, type of cell therapy, procedural characteristics, outcome measure, method for measuring strain, and efficacy on both LVEF and deformation parameters were depicted. A total of 30 studies, 15 preclinical and 15 clinical, were included for analysis. Deformation outcomes improved significantly in 14 out of 15 preclinical studies and in 10 out of 15 clinical studies, whereas LVEF improved in 12 and 4 articles, respectively. Study designs and used deformation outcomes varied significantly among the included papers. Six studies found a positive effect on deformation outcomes without LVEF improvement. Hence, deformation imaging seems at least equal, and perhaps superior, to LVEF measurement in the assessment of cardiac regenerative therapy. However, strategies varied substantially and call for a standardized approach.

show abstract

HRS Policy Statement: Clinical Cardiac Electrophysiology Fellowship Curriculum: Update 2011

et al. 2011

View full text Add to dashboard Cite

Evolving Anatomic, Functional, and Molecular Imaging in the Early Detection and Prognosis of Hypertrophic Cardiomyopathy

Cited by 4 publications

References 74 publications

Comparison of Echocardiographic and Cardiac Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers Without Left Ventricular Hypertrophy

Comparison of Echocardiographic and Cardiac Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers Without Left Ventricular Hypertrophy

Deformation imaging to assess global and regional effects of cardiac regenerative therapy in ischaemic heart disease: A systematic review

HRS Policy Statement: Clinical Cardiac Electrophysiology Fellowship Curriculum: Update 2011

Contact Info

Product

Resources

About